Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT-108 in mild to moderate knee osteoarthritis
NCT06263270Phase 1Completed
- Sponsor
- Cytonics Corporation
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing Active Treatment Arm (CYT-108) with Placebo Control Arm (PBS) (2 arms). Primary endpoints: Adverse Events at 26 weeks, Blood Pressure at 26 weeks and 4 more. Started Jun 2024; status: completed.
02
Drugs
CYT-108
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06263270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263270.